60 Degrees Pharmaceuticals, Inc. (60P), a company specializing in infectious disease treatments, has entered into a Research Services Agreement with Monash University through its majority-owned Australian subsidiary, 60P Australia Pty Ltd. The agreement, effective as of February 5, 2024, involves Monash University providing research services to test the efficacy of the drug tafenoquine against candidemia, a fungal infection. The research will also determine the appropriate dosage for fungal infections and study the pharmacokinetics of the drug following intraperitoneal administration. The experiments are set to begin in May 2024, with completion expected by November 30, 2024. 60P has agreed to pay Monash University $90,167 AUD on April 1, 2024, and the same amount upon completion of the services. The agreement can be terminated by either party under certain conditions, including breach of...Show More

60 Degrees Pharmaceuticals, Inc. (60P), a company specializing in infectious disease treatments, has entered into a Research Services Agreement with Monash University through its majority-owned Australian subsidiary, 60P Australia Pty Ltd. The agreement, effective as of February 5, 2024, involves Monash University providing research services to test the efficacy of the drug tafenoquine against candidemia, a fungal infection. The research will also determine the appropriate dosage for fungal infections and study the pharmacokinetics of the drug following intraperitoneal administration. The experiments are set to begin in May 2024, with completion expected by November 30, 2024. 60P has agreed to pay Monash University $90,167 AUD on April 1, 2024, and the same amount upon completion of the services. The agreement can be terminated by either party under certain conditions, including breach of contract or insolvency. Additionally, Monash University retains the right to terminate the agreement if the services contravene Australian Sanctions Law. On February 20, 2024, 60P issued a press release announcing the sponsorship of pre-clinical studies to investigate tafenoquine's efficacy against Candida spp, including the drug-resistant Candida auris. The studies, to be conducted by Monash University, are expected to yield results by the end of 2024. Tafenoquine is an FDA-approved anti-malarial drug, and the study aims to explore its potential use against fungal infections.